Literature DB >> 11740341

The genetic determinants of the CYP3A5 polymorphism.

E Hustert1, M Haberl, O Burk, R Wolbold, Y Q He, K Klein, A C Nuessler, P Neuhaus, J Klattig, R Eiselt, I Koch, A Zibat, J Brockmöller, J R Halpert, U M Zanger, L Wojnowski.   

Abstract

CYP3A proteins comprise a significant portion of the hepatic cytochrome P450 (CYP) protein and they metabolize around 50% of drugs currently in use. The dissection of the individual contributions of the four CYP3A genes identified in humans to overall hepatic CYP3A activity has been hampered by sequence and functional similarities. We have investigated the expression of CYP3A5 and its genetic determinants in a panel of 183 Caucasian liver samples. CYP3A5 expression is increased in 10% of livers in this ethnic group. Using a high density map of CYP3A5 variants, we searched for genetic markers of the increased CYP3A5 expression. In agreement with an independent, recent study, we report that a SNP within intron 3 (g.6986G>A) is the primary cause of the CYP3A5 protein polymorphism. The frequencies of the g.6986A variant which allow for normal splicing of CYP3A5 transcripts are 5% in Caucasians, 29% in Japanese, 27% in Chinese, 30% in Koreans and 73% in African-Americans. In the last ethnic group, the expression of CYP3A5 in some individuals who carry the g.6986A variant is affected adversely by a frame shift mutation (CYP3A5*7, D348., q = 0.10). In summary, these results should add to efforts to identify clinically relevant, CYP3A5-specific reactions and to further elucidate traits responsible for variable expression of the entire CYP3A family.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740341     DOI: 10.1097/00008571-200112000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  160 in total

1.  Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.

Authors:  Nayoung Han; Hwi-yeol Yun; Jin-yi Hong; In-Wha Kim; Eunhee Ji; Su Hyun Hong; Yon Su Kim; Jongwon Ha; Wan Gyoon Shin; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

3.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 4.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

5.  CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

Authors:  C Balram; Qingyu Zhou; Yin Bun Cheung; Edmund J D Lee
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

6.  CYP3A5 phenotype-genotype correlations in a British population.

Authors:  Barry P King; Julian B S Leathart; Elaine Mutch; Faith M Williams; Ann K Daly
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

7.  Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.

Authors:  Landry K Kamdem; Ingolf Meineke; Ina Koch; Ulrich M Zanger; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-01       Impact factor: 3.000

8.  Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

Authors:  Pei-Chieng Cha; Ryo Yamada; Akihiro Sekine; Yusuke Nakamura; Chong-Lek Koh
Journal:  J Hum Genet       Date:  2004-09-11       Impact factor: 3.172

9.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

10.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.